Likewise, cisplatin-gemcitabine is cost-effective as a first-line therapy compared with erlotinib for advanced EGFR wild-type NSCLC [53] whereas our study showed that erlotinib is cost-effectiveness as first-line therapy compared with cisplatin-gemcitabine for advanced EGFR mutation-positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.